China NT Pharma : VOLUNTARY ANNOUNCEMENT SELECTION RESULTS OF NATIONAL CENTRALIZED PHARMACEUTICALS PROCUREMENT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01011)

VOLUNTARY ANNOUNCEMENT

SELECTION RESULTS OF

NATIONAL CENTRALIZED PHARMACEUTICALS

PROCUREMENT

This is a voluntary announcement made by China NT Pharma Group Company Limited (the "Company", and together with its subsidiaries, the "Group").

The Company hereby announces that quetiapine fumarate ("Shusi") of the Group has

been selected in the tender for National Centralized Pharmaceuticals Procurement* (全國藥品集中採購) in the PRC on 20 August 2020, and the relevant selection result is

stated below:

The board of directors expects that the successful selection will have a positive impact on the sales of Shusi; Shusi will be exclusively supplied to Jiangsu, Guangdong, Hubei, Hebei, Yunnan, Shaanxi, Guangxi, Tianjin, Gansu and Qinghai provinces under the procurement contracts; and the Group will further increase the sales and market share of Shusi through these procurement contracts, bringing growth momentum to Shusi's future sales revenue.

1

Suzhou First Pharmaceutical Co., Ltd., a subsidiary of the Group, produces the brand-name drug "Shusi" (quetiapine fumarate tablets), which is within the scope of the guidelines for the treatment of schizophrenia and bipolar disorder issued by the Chinese Medical Association, and is listed on the National Reimbursement Drug List and the National Essential Drug List (Category A). Shusi is a proprietary product of Suzhou First . In December 2013, Shusi was approved by the China Food and Drug Administration for the treatment of bipolar affective disorder. Shusi is an atypical antipsychotic drug which has proven safety track records and therapeutic effects on first-time psychiatric patients, elderly patients and adolescent patients. As a drug listed on both the National Reimbursement Drug List and the National Essential Drugs List, Shusi is a state approved prescription medicine.

Shareholders and potential investors of the Company should exercise caution when dealing in securities of the Company.

By order of the Board

China NT Pharma Group Company Limited

NG Tit

Chairman

Hong Kong, 20 August 2020

As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Tze Shan Hailson Yu, Mr. Pan Fei and Dr. Zhao Yubiao.

• For identification purpose only

2